Physician profile
Michael Capicotto
NPI 1366495095
$2,113.73
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $547 · 2020: $41.48 · 2021: $1,074 · 2022: $436 · 2024: $15.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $15.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $15.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $394.24 | 2019-2022 | |
| Amgen INC. | $216.08 | 2019-2022 | |
| Harmony Biosciences LLC | $202.90 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $154.76 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $131.02 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $119.49 | 2019 | |
| Genzyme Corporation | $104.31 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $97.76 | 2021-2022 | |
| Opko Pharmaceuticals, LLC | $89.93 | 2021-2024 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $88.37 | 2021-2022 | |
| Horizon Therapeutics Plc | $85.65 | 2021-2022 | |
| Akebia Therapeutics INC | $72.21 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $68.67 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $48.21 | 2019 | |
| Aurinia Pharma U.S., INC. | $47.99 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $39.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.57 | 2019 | |
| Glaxosmithkline, LLC. | $22.50 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.64 | 2021 | |
| Novo Nordisk INC | $15.58 | 2019 | |
| Allergan, INC. | $15.35 | 2019 | |
| Electromed, INC. | $14.99 | 2019 | |
| Abbott Laboratories | $14.83 | 2019 | |
| Merck Sharp & Dohme LLC | $13.52 | 2021 | |
| Amarin Pharma, INC. | $13.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Capicotto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.